Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON
Gothenburg, January 17, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announced that the company's Chief Scientific Officer and co-founder, Professor Magnus Essand, has received a prestigious speaking invitation from the Eighth International Cancer Immunotherapy Conference (CICON).CICON is the world's largest recurring conference in the field of cancer immunotherapy and is being held this year in Washington, DC, between September 8 and 11.